It is a randomized placebo controlled study, the aim was to study the efficacy and safety of one of phytotherapeutic agents (Serenoa repens) in treating symptomatic BPH compared to placebo, for three months. Our patients were above 50 years; they were selected according to strict inclusion and exclusion criteria. Out of 89 patients, only 50 patients had completed the study. The highest percentage of drop out was in the placebo group, subjective and objective improvements were found maximal in permixon group. Safety was ensured with no serious adverse effects were found.